.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
McKesson
Covington
Harvard Business School
Medtronic
Colorcon
Citi
Dow
Chinese Patent Office

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,689,761

« Back to Dashboard

Which drugs does patent 6,689,761 protect, and when does it expire?


Patent 6,689,761 protects CRIXIVAN and is included in one NDA.

This patent has forty-one patent family members in thirty-five countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,689,761

Title: Combination therapy for HIV infection
Abstract:The combination of the HIV protease inhibitor Compound J, 3TC, and, optionally AZT, ddI, or ddC, is useful in the inhibition of HIV protease, the inhibition of HIV reverse transcriptase, the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds, pharmaceutically acceptable salts, pharmaceutical composition ingredients, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
Inventor(s): Chodakewitz; Jeffrey A. (Gwynedd Valley, PA), Emini; Emilio A. (Paoli, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:08/382,113
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-006Apr 19, 2000DISCNNoNo► Subscribe► Subscribe► SubscribeTREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-003Mar 13, 1996RXYesNo► Subscribe► Subscribe► SubscribeTREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-005Dec 17, 1998DISCNNoNo► Subscribe► Subscribe► SubscribeTREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
Merck Sharp DohmeCRIXIVANindinavir sulfateCAPSULE;ORAL020685-001Mar 13, 1996RXYesYes► Subscribe► Subscribe► SubscribeTREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,689,761

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China1160081► Subscribe
Colombia4700430► Subscribe
Czech Republic9702444► Subscribe
Germany69628819► Subscribe
Denmark0806957► Subscribe
Algeria1988► Subscribe
Eurasian Patent Organization000437► Subscribe
Estonia9700165► Subscribe
Estonia03514► Subscribe
European Patent Office0806957► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Citi
Cerilliant
Chubb
US Department of Justice
Argus Health
Colorcon
Medtronic
Cantor Fitzgerald
Teva
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot